News und Analysen
Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera
Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today presented additional data
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Mitie Group plc
Form 8.3 - The Vanguard Group, Inc.: Mitie Group plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Mitie Group plc
Form 8.3 - The Vanguard Group, Inc.: Mitie Group plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc